Please login to the form below

Not currently logged in
Email:
Password:

Epclusa

This page shows the latest Epclusa news and features for those working in and with pharma, biotech and healthcare.

AbbVie sues NHS England over hep C procurement

AbbVie sues NHS England over hep C procurement

treatment – as well as follow-up combinations such as Harvoni (sofosbuvir/ledipasvir) as well as Epclusa (sofosbuvir/velpatasvir) that was effective against all HCV genotypes.

Latest news

  • Merck & Co pulls out of hepatitis C R&D as market shrinks Merck & Co pulls out of hepatitis C R&D as market shrinks

    In the same period, Gilead’s HCV portfolio of Harvoni (sofosbuvir/ledipasvir), Epclusa (sofosbuvir/velpatasvir) and Sovaldi (sofosbuvir) brought in $5.44bn, down from around $8.3bn in the first half

  • Gilead gets OK for three-in-one hep C therapy in US Gilead gets OK for three-in-one hep C therapy in US

    The single-tablet triple therapy contains NS5B polymerase inhibitor sofosbuvir and NS5A inhibitor velpatasvir - the two active ingredients in Gilead's recently-approved two-drug HCV combination Epclusa - as well as ... Sovaldi and follow-ups Harvoni and

  • Two new hepatitis C therapies fast-tracked in Europe Two new hepatitis C therapies fast-tracked in Europe

    It is dosed once daily as three oral tablets and is being billed as a rival to Epclusa, which is dosed over 12 weeks in all patients. ... Analysts at Leerink have previously predicted that combined sales of Harvoni, Sovaldi and Epclusa will be $2.5bn a

  • Gilead files hepatitis C salvage regimen in US Gilead files hepatitis C salvage regimen in US

    The two other studies - POLARIS-2 and 3 - compared the triple combination regimen in treatment-naïve patients given for eight weeks to Epclusa given for 12 weeks. ... The SVR rates were comparable between the new regimen and Epclusa in both trials.

  • SMC approves Opdivo combo as first-line skin cancer treatment SMC approves Opdivo combo as first-line skin cancer treatment

    Also backs Gilead’s Epclusa, Baxalta’s Oncaspar, AZ’s Lynparza and Amicus’ Galafold. ... Meanwhile, Gilead Sciences' chronic hepatitis C virus infection therapy Epclusa (sofosbuvir/velpatasvir) received SMC backing for the treatment of patients

More from news
Approximately 8 fully matching, plus 4 partially matching documents found.

Latest Intelligence

  • Deal Watch October 2018

    In other news from Gilead, the company has created a new subsidiary, Asegua Therapeutics, which will launch authorised generic versions of Epclusa and Harvoni, Gilead’s treatments for hepatits C virus

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Fishawack Group of Companies

The Fishawack Group of Companies is one of the largest independent medical communications and medical marketing specialists, with teams in...

Latest intelligence

The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....
Escaping the spin cycle of sub-optimal launch
...

Infographics